Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 872152, 9 pages
http://dx.doi.org/10.1155/2015/872152
Review Article

Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis

1Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
2Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan

Received 19 May 2015; Revised 8 July 2015; Accepted 13 July 2015

Academic Editor: Ekihiro Seki

Copyright © 2015 Hiroki Nishikawa and Yukio Osaki. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Moriwaki, Y. Miwa, M. Tajika, M. Kato, H. Fukushima, and M. Shiraki, “Branched-chain amino acids as a protein- and energy-source in liver cirrhosis,” Biochemical and Biophysical Research Communications, vol. 313, no. 2, pp. 405–409, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. M. R. Charlton, “Branched-chain amino acid enriched supplements as therapy for liver disease,” Journal of Nutrition, vol. 136, no. 1, supplement, pp. 295S–298S, 2006. View at Google Scholar · View at Scopus
  3. Y. Imai, S. Tamura, H. Tanaka et al., “Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders,” Journal of Viral Hepatitis, vol. 17, no. 3, pp. 185–191, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Arase, K. Ikeda, F. Suzuki et al., “Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C,” Intervirology, vol. 50, no. 1, pp. 16–23, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Schuppan and N. H. Afdhal, “Liver cirrhosis,” The Lancet, vol. 371, no. 9615, pp. 838–851, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Castera, “Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease,” Best Practice and Research: Clinical Gastroenterology, vol. 25, no. 2, pp. 291–303, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Chrostek and A. Panasiuk, “Liver fibrosis markers in alcoholic liver disease,” World Journal of Gastroenterology, vol. 20, no. 25, pp. 8018–8023, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Sumida, A. Nakajima, and Y. Itoh, “Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis,” World Journal of Gastroenterology, vol. 20, no. 2, pp. 475–485, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. J. O. Smith and R. K. Sterling, “Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C,” Alimentary Pharmacology and Therapeutics, vol. 30, no. 6, pp. 557–576, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. D'Onofrio, S. Crosara, R. de Robertis et al., “Acoustic radiation force impulse of the liver,” World Journal of Gastroenterology, vol. 19, no. 30, pp. 4841–4849, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. K. Mariappan, K. J. Glaser, and R. L. Ehman, “Magnetic resonance elastography: a review,” Clinical Anatomy, vol. 23, no. 5, pp. 497–511, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M.-L. Yu, S.-M. Lin, C.-M. Lee et al., “A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy,” Hepatology, vol. 44, no. 5, pp. 1086–1097, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Castera, “Noninvasive methods to assess liver disease in patients with hepatitis B or C,” Gastroenterology, vol. 142, no. 6, pp. 1293–1302, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Toshikuni, T. Arisawa, and M. Tsutsumi, “Nutrition and exercise in the management of liver cirrhosis,” World Journal of Gastroenterology, vol. 20, no. 23, pp. 7286–7297, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Montano-Loza, “Clinical relevance of sarcopenia in patients with cirrhosis,” World Journal of Gastroenterology, vol. 20, no. 25, pp. 8061–8071, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. C. G. Child, “Surgery and portal hypertension,” in The Liver and Portal Hypertension, pp. 50–72, WB Saunders, Philadelphia, Pa, USA, 1964. View at Google Scholar
  17. “A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators,” Hepatology, vol. 28, no. 3, pp. 751–755, 1998. View at Scopus
  18. J. M. Llovet, C. Brú, and J. Bruix, “Prognosis of hepatocellular carcinoma: the BCLC staging classification,” Seminars in Liver Disease, vol. 19, no. 3, pp. 329–337, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Kudo, H. Chung, and Y. Osaki, “Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score),” Journal of Gastroenterology, vol. 38, no. 3, pp. 207–215, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Nishikawa, R. Kita, T. Kimura et al., “Clinical implication of performance status in patients with hepatocellular carcinoma complicating with cirrhosis,” Journal of cancer, vol. 6, no. 4, pp. 394–402, 2015. View at Publisher · View at Google Scholar
  21. M. Malinchoc, P. S. Kamath, F. D. Gordon, C. J. Peine, J. Rank, and P. C. J. Ter Borg, “A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts,” Hepatology, vol. 31, no. 4, pp. 864–871, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Vitale, M. L. Volk, T. M. De Feo et al., “A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list,” Journal of Hepatology, vol. 60, no. 2, pp. 290–297, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. W. R. Kim, S. W. Biggins, W. K. Kremers et al., “Hyponatremia and mortality among patients on the liver-transplant waiting list,” The New England Journal of Medicine, vol. 359, no. 10, pp. 1018–1026, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Nishikawa, R. Kita, T. Kimura et al., “Hyponatremia in hepatocellular carcinoma complicating with cirrhosis,” Journal of Cancer, vol. 6, no. 5, pp. 482–489, 2015. View at Publisher · View at Google Scholar
  25. C. Ripoll, R. Bañares, D. Rincón et al., “Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era,” Hepatology, vol. 42, no. 4, pp. 793–801, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. G. D'Amico, G. Garcia-Tsao, and L. Pagliaro, “Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies,” Journal of Hepatology, vol. 44, no. 1, pp. 217–231, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Arvaniti, G. D'Amico, G. Fede et al., “Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis,” Gastroenterology, vol. 139, no. 4, pp. 1246.e1–1256.e5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Fede, G. D'Amico, V. Arvaniti et al., “Renal failure and cirrhosis: a systematic review of mortality and prognosis,” Journal of Hepatology, vol. 56, no. 4, pp. 810–818, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Vergniol, J. Foucher, E. Terrebonne et al., “Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C,” Gastroenterology, vol. 140, no. 7, pp. 1970–1979, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Singh, L. L. Fujii, M. H. Murad et al., “Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis,” Clinical Gastroenterology and Hepatology, vol. 11, no. 12, pp. 1573–1584, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Takuma, K. Nouso, Y. Morimoto et al., “Measurement of spleen stiffness by acoustic radiation force impulse imaging identifies cirrhotic patients with esophageal varices,” Gastroenterology, vol. 144, no. 1, pp. 92–101, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Nishikawa, Y. Osaki, H. Komekado et al., “Clinical implication of the preoperative GSA index in 99mTc-GSA scintigraphy in hepatitis C virus-related hepatocellular carcinoma,” Oncology Reports, vol. 33, no. 3, pp. 1071–1078, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Nishikawa, Y. Osaki, H. Komekado et al., “Clinical significance of the FIB-4 index for non-B non-C hepatocellular carcinoma treated with surgical resection,” Oncology Reports, vol. 33, no. 1, pp. 88–94, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Toshima, K. Shirabe, T. Ikegami et al., “A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), for assessing liver fibrosis,” Journal of Gastroenterology, vol. 50, no. 1, pp. 76–84, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Yamasaki, M. Tateyama, S. Abiru et al., “Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients,” Hepatology, vol. 60, no. 5, pp. 1563–1570, 2014. View at Publisher · View at Google Scholar
  36. T. Hanai, M. Shiraki, K. Nishimura et al., “Sarcopenia impairs prognosis of patients with liver cirrhosis,” Nutrition, vol. 31, no. 1, pp. 193–199, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. T. M. Johnson, E. B. Overgard, A. E. Cohen, and J. K. Dibaise, “Nutrition assessment and management in advanced liver disease,” Nutrition in Clinical Practice, vol. 28, no. 1, pp. 15–29, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Hasse, S. Strong, M. A. Gorman, and G. Liepa, “Subjective global assessment: alternative nutrition-assessment technique for liver-transplant candidates,” Nutrition, vol. 9, no. 4, pp. 339–343, 1993. View at Google Scholar · View at Scopus
  39. S. A. Fernandes, L. Bassani, F. F. Nunes, M. E. D. Aydos, A. V. Alves, and C. A. Marroni, “Nutritional assessment in patients with cirrhosis,” Arquivos de Gastroenterologia, vol. 49, no. 1, pp. 19–27, 2012. View at Google Scholar · View at Scopus
  40. J. Ignacio de Ulíbarri, A. González-Madroño, N. G. P. de Villar et al., “CONUT: a tool for controlling nutritional status. First validation in a hospital population,” Nutricion Hospitalaria, vol. 20, no. 1, pp. 38–45, 2005. View at Google Scholar · View at Scopus
  41. A. González-Madroño, A. Mancha, F. J. Rodríguez, J. Culebras, and J. I. de Ulíbarri, “Confirming the validity of the CONUT system for early detection and monitoring of clinical undernutrition; comparison with two logistic regression models developed using SGA as the gold standard,” Nutrición Hospitalaria, vol. 27, no. 2, pp. 564–571, 2012. View at Google Scholar
  42. W.-T. Chang, C.-G. Ker, H.-C. Hung et al., “Albumin and prealbumin may predict retinol status in patients with liver cirrhosis,” Hepato-Gastroenterology, vol. 55, no. 86-87, pp. 1681–1685, 2008. View at Google Scholar · View at Scopus
  43. C. Roongpisuthipong, A. Sobhonslidsuk, K. Nantiruj, and S. Songchitsomboon, “Nutritional assessment in various stages of liver cirrhosis,” Nutrition, vol. 17, no. 9, pp. 761–765, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Gunsar, M. L. Raimondo, S. Jones et al., “Nutritional status and prognosis in cirrhotic patients,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 4, pp. 563–572, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Abad-Lacruz, E. Cabré, F. González-Huix et al., “Routine tests of renal function, alcoholism, and nutrition improve the prognostic accuracy of Child-Pugh score in nonbleeding advanced cirrhotics,” American Journal of Gastroenterology, vol. 88, no. 3, pp. 382–387, 1993. View at Google Scholar · View at Scopus
  46. N. Panagaria, K. Varma, S. Nijhawan, A. Mathur, and R. R. Rai, “Comparison of nutritional status between patients with alcoholic and non-alcoholic liver cirrhosis,” Tropical Gastroenterology, vol. 27, no. 2, pp. 75–79, 2006. View at Google Scholar · View at Scopus
  47. P. Tandon, M. Ney, I. Irwin et al., “Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value,” Liver Transplantation, vol. 18, no. 10, pp. 1209–1216, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. A. J. Montano-Loza, J. Meza-Junco, C. M. M. Prado et al., “Muscle wasting is associated with mortality in patients with cirrhosis,” Clinical Gastroenterology and Hepatology, vol. 10, no. 2, pp. 166–173, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Dasarathy, “Consilience in sarcopenia of cirrhosis,” Journal of Cachexia, Sarcopenia and Muscle, vol. 3, no. 4, pp. 225–237, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. M. J. Englesbe, S. P. Patel, K. He et al., “Sarcopenia and mortality after liver transplantation,” Journal of the American College of Surgeons, vol. 211, no. 2, pp. 271–278, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. I. H. Rosenberg, “Sarcopenia: origins and clinical relevance,” Journal of Nutrition, vol. 127, supplement 5, pp. 990S–991S, 1997. View at Google Scholar
  52. C. Wang and L. Bai, “Sarcopenia in the elderly: basic and clinical issues,” Geriatrics and Gerontology International, vol. 12, no. 3, pp. 388–396, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. M. E. Levine and E. M. Crimmins, “The impact of insulin resistance and inflammation on the association between sarcopenic obesity and physical functioning,” Obesity, vol. 20, no. 10, pp. 2101–2106, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. H. C. Hong, S. Y. Hwang, H. Y. Choi et al., “Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study,” Hepatology, vol. 59, no. 5, pp. 1772–1778, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Hiraoka, T. Aibiki, T. Okudaira et al., “Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: computed tomography is useful for evaluation,” Journal of Gastroenterology, 2015. View at Publisher · View at Google Scholar
  56. S. Hirsch, D. Bunout, P. de la Maza et al., “Controlled trial on nutrition supplementation in outpatients with symptomatic alcoholic cirrhosis,” Journal of Parenteral and Enteral Nutrition, vol. 17, no. 2, pp. 119–124, 1993. View at Publisher · View at Google Scholar · View at Scopus
  57. A. J. Cruz-Jentoft, J. P. Baeyens, J. M. Bauer et al., “Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People,” Age and Ageing, vol. 39, no. 4, pp. 412–423, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Masuda, K. Shirabe, T. Ikegami et al., “Sarcopenia is a prognostic factor in living donor liver transplantation,” Liver Transplantation, vol. 20, no. 4, pp. 401–407, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Tsien, S. N. Shah, A. J. McCullough, and S. Dasarathy, “Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent,” European Journal of Gastroenterology and Hepatology, vol. 25, no. 1, pp. 85–93, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. F. Durand, S. Buyse, C. Francoz et al., “Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography,” Journal of Hepatology, vol. 60, no. 6, pp. 1151–1157, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Y. Kim, M. Y. Kim, J. H. Sohn et al., “Sarcopenia as a useful predictor for long-term mortality in cirrhotic patients with ascites,” Journal of Korean Medical Science, vol. 29, no. 9, pp. 1253–1259, 2014. View at Publisher · View at Google Scholar
  62. K. Norman, M. Pirlich, J. Sorensen et al., “Bioimpedance vector analysis as a measure of muscle function,” Clinical Nutrition, vol. 28, no. 1, pp. 78–82, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. F. Antaki, M. M. French, D. K. Moonka, and S. C. Gordon, “Bioelectrical impedance analysis for the evaluation of hepatic fibrosis in patients with chronic hepatitis C infection,” Digestive Diseases and Sciences, vol. 53, no. 7, pp. 1957–1960, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. F. A. F. Figueiredo, R. M. Perez, M. M. Freitas, and M. Kondo, “Comparison of three methods of nutritional assessment in liver cirrhosis: subjective global assessment, traditional nutritional parameters, and body composition analysis,” Journal of Gastroenterology, vol. 41, no. 5, pp. 476–482, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Fiore, M. Merli, A. Andreoli et al., “A comparison of skinfold anthropometry and dual-energy X-ray absorptiometry for the evaluation of body fat in cirrhotic patients,” Clinical Nutrition, vol. 18, no. 6, pp. 349–351, 1999. View at Publisher · View at Google Scholar · View at Scopus
  66. A. M. Madden and M. Y. Morgan, “The potential role of dual-energy X-ray absorptiometry in the assessment of body composition in cirrhotic patients,” Nutrition, vol. 13, no. 1, pp. 40–45, 1997. View at Publisher · View at Google Scholar · View at Scopus
  67. H. Yovita, A. Djumhana, S. A. Abdurachman, and J. R. Saketi, “Correlation between anthropometrics measurements, prealbumin level and transferin serum with Child-Pugh classification in evaluating nutritional status of liver cirrhosis patient,” Acta Medica Indonesiana, vol. 36, no. 4, pp. 197–201, 2004. View at Google Scholar · View at Scopus
  68. M. Zamboni, G. Mazzali, F. Fantin, A. Rossi, and V. Di Francesco, “Sarcopenic obesity: a new category of obesity in the elderly,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 18, no. 5, pp. 388–395, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Shiraki, S. Nishiguchi, M. Saito et al., “Nutritional status and quality of life in current patients with liver cirrhosis as assessed in 2007–2011,” Hepatology Research, vol. 43, no. 2, pp. 106–112, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Nishikawa and Y. Osaki, “Non-B, non-C hepatocellular carcinoma (review),” International Journal of Oncology, vol. 43, no. 5, pp. 1333–1342, 2013. View at Google Scholar
  71. C. M. M. Prado, J. C. K. Wells, S. R. Smith, B. C. M. Stephan, and M. Siervo, “Sarcopenic obesity: a Critical appraisal of the current evidence,” Clinical Nutrition, vol. 31, no. 5, pp. 583–601, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. P. Srikanthan and A. S. Karlamangla, “Relative muscle mass is inversely associated with insulin resistance and prediabetes: findings from the third National Health and Nutrition Examination Survey,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, pp. 2898–2903, 2011. View at Google Scholar
  73. N. S. Choudhary, S. Saigal, N. Saraf et al., “Sarcopenic obesity with metabolic syndrome: a newly recognized entity following living donor liver transplantation,” Clinical Transplantation, vol. 29, no. 3, pp. 211–215, 2015. View at Publisher · View at Google Scholar · View at Scopus
  74. G. M. Chertow, E. G. Lowrie, D. W. Wilmore et al., “Nutritional assessment with bioelectrical impedance analysis in maintenance hemodialysis patients,” Journal of the American Society of Nephrology, vol. 6, no. 1, pp. 75–81, 1995. View at Google Scholar · View at Scopus
  75. S. M. Grundy, H. B. Brewer Jr., J. I. Cleeman, S. C. Smith Jr., and C. Lenfant, “Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, pp. e13–e18, 2004. View at Google Scholar
  76. H. Nishikawa and Y. Osaki, “Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma,” Hepatology Research, vol. 44, no. 2, pp. 149–158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. C. Bémeur and R. F. Butterworth, “Nutrition in the management of cirrhosis and its neurological complications,” Journal of Clinical and Experimental Hepatology, vol. 4, no. 2, pp. 141–150, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Andersen, M. Borre, J. Jakobsen, P. H. Andersen, and H. Vilstrup, “Decreased muscle strength in patients with alcoholic liver cirrhosis in relation to nutritional status, alcohol abstinence, liver function, and neuropathy,” Hepatology, vol. 27, no. 5, pp. 1200–1206, 1998. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Hayashi, K. Ikezawa, A. Ono et al., “Evaluation of the effects of combination therapy with branched-chain amino acid and zinc supplements on nitrogen metabolism in liver cirrhosis,” Hepatology Research, vol. 37, no. 8, pp. 615–619, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. K. Katayama, M. Saito, T. Kawaguchi et al., “Effect of zinc on liver cirrhosis with hyperammonemia: a preliminary randomized, placebo-controlled double-blind trial,” Nutrition, vol. 30, no. 11-12, pp. 1409–1414, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. M. H. Somi, P. Rezaeifar, A. O. Rahimi, and B. Moshre, “Effects of low dose zinc supplementation on biochemical markers in non-alcoholic cirrhosis: a randomized clinical trial,” Archives of Iranian Medicine, vol. 15, no. 8, pp. 472–476, 2012. View at Google Scholar · View at Scopus
  82. T. Kawaguchi, N. Izumi, M. R. Charlton, and M. Sata, “Branched-chain amino acids as pharmacological nutrients in chronic liver disease,” Hepatology, vol. 54, no. 3, pp. 1063–1070, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Muto, S. Sato, A. Watanabe et al., “Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis,” Clinical Gastroenterology and Hepatology, vol. 3, no. 7, pp. 705–713, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. H. Moriwaki, M. Shiraki, H. Fukushima et al., “Long-term outcome of branched-chain amino acid treatment in patients with liver cirrhosis,” Hepatology Research, vol. 38, no. 1, pp. S102–S106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Hayaishi, H. Chung, M. Kudo et al., “Oral branched-chain amino acid granules reduce the incidence of Hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis,” Digestive Diseases, vol. 29, no. 3, pp. 326–332, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Yoshiji, R. Noguchi, K. Kaji et al., “Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats,” Journal of Gastroenterology, vol. 45, no. 4, pp. 443–450, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. H. Yoshiji, R. Noguchi, M. Kitade et al., “Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats,” Journal of Gastroenterology, vol. 44, no. 5, pp. 483–491, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. T. Ohno, Y. Tanaka, F. Sugauchi et al., “Suppressive effect of oral administration of branched-chain amino acid granules on oxidative stress and inflammation in HCV-positive patients with liver cirrhosis,” Hepatology Research, vol. 38, no. 7, pp. 683–688, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. H. Kumada, T. Okanoue, M. Onji et al., “Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan,” Hepatology Research, vol. 40, no. 1, pp. 8–13, 2010. View at Publisher · View at Google Scholar
  90. ASPEN Board of Directors and the Clinical Guidelines Task Force, “Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients,” Journal of Parenteral and Enteral Nutrition, vol. 26, no. 1, supplement, pp. 1SA–138SA, 2002. View at Publisher · View at Google Scholar
  91. M. Plauth, E. Cabré, O. Riggio et al., “ESPEN guidelines on enteral nutrition: liver disease,” Clinical Nutrition, vol. 25, no. 2, pp. 285–294, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Krähenbühl and J. Reichen, “Carnitine metabolism in patients with chronic liver disease,” Hepatology, vol. 25, no. 1, pp. 148–153, 1997. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Malaguarnera, M. P. Gargante, E. Cristaldi et al., “Acetyl-L-carnitine treatment in minimal hepatic encephalopathy,” Digestive Diseases and Sciences, vol. 53, no. 11, pp. 3018–3025, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. H. Nakanishi, M. Kurosaki, K. Tsuchiya et al., “L-carnitine reduces muscle cramps in patients with cirrhosis,” Clinical Gastroenterology and Hepatology, vol. 13, no. 8, pp. 1540–1543, 2015. View at Publisher · View at Google Scholar
  95. M. M. Oken, R. H. Creech, and D. C. Tormey, “Toxicology and response criteria of the Eastern Cooperative Oncology Group,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 5, no. 6, pp. 649–655, 1982. View at Google Scholar · View at Scopus
  96. J. Bruix, M. Sherman, and Practice Guidelines Committee for AASLD, “Management of hepatocellular carcinoma,” Hepatology, vol. 42, no. 5, pp. 1208–1236, 2005. View at Publisher · View at Google Scholar · View at Scopus
  97. H. Nishikawa, R. Kita, T. Kimura et al., “Proposal of performance status combined Japan integrated Staging system in hepatocellular carcinoma complicating with cirrhosis,” International Journal of Oncology, vol. 46, no. 6, pp. 2371–2379, 2015. View at Google Scholar
  98. N. Fujiwara, H. Nakagawa, Y. Kudo et al., “Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma,” Journal of Hepatology, vol. 63, no. 1, pp. 131–140, 2015. View at Publisher · View at Google Scholar
  99. Y. Hamaguchi, T. Kaido, S. Okumura et al., “Preoperative intramuscular adipose tissue content is a novel prognostic predictor after hepatectomy for hepatocellular carcinoma,” Journal of Hepato-Biliary-Pancreatic Sciences, vol. 22, no. 6, pp. 475–485, 2015. View at Publisher · View at Google Scholar
  100. V. Valero III, N. Amini, G. Spolverato et al., “Sarcopenia adversely impacts postoperative complications following resection or transplantation in patients with primary liver tumors,” Journal of Gastrointestinal Surgery, vol. 19, no. 2, pp. 272–281, 2015. View at Publisher · View at Google Scholar
  101. T. Voron, L. Tselikas, D. Pietrasz et al., “Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma,” Annals of Surgery. In press.
  102. H. Otsuji, Y. Yokoyama, T. Ebata et al., “Preoperative sarcopenia negatively impacts postoperative outcomes following major hepatectomy with extrahepatic bile duct resection,” World Journal of Surgery, vol. 39, no. 6, pp. 1494–1500, 2015. View at Publisher · View at Google Scholar
  103. R. M. Dodson, A. Firoozmand, O. Hyder et al., “Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies,” Journal of Gastrointestinal Surgery, vol. 17, no. 12, pp. 2123–2132, 2013. View at Publisher · View at Google Scholar · View at Scopus
  104. O. Mir, R. Coriat, B. Blanchet et al., “Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma,” PLoS ONE, vol. 7, no. 5, Article ID e37563, 2012. View at Publisher · View at Google Scholar · View at Scopus